Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangmin Tong

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Cancers|September 28, 2024
Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug CandidatesLingyan Yu, Yuyueyang Qiu, Xiangmin Tong
Frontiers in Immunology|June 1, 2026
Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistanceXiaozhen Kang, Xiangmin Tong, Shibing Wang
International Journal of Hematology|December 3, 2013
Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutationWeiyi Xu, Baode Chen, Xiangmin Tong
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|July 17, 2019
[Effects of aerobic glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma]Li Xu, Ming Xu, Xiangmin Tong
Frontiers in Pharmacology|March 28, 2019
Carbon-Based Nanomaterials for Biomedical Applications: A Recent StudyDebabrata Maiti, Xiangmin Tong, Xiaozhou Mou, et al.
International Journal of Medical Sciences|September 17, 2025
Overcoming the Delivery Challenges in CRISPR/Cas9 Gene Editing for Effective Cancer Treatment: A Review of Delivery SystemsShuting Tang, Xiaoyi Chen, Xiangmin Tong, et al.
Cell Death & Disease|December 21, 2021
WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemiaYunqi Zhu, Xiangmin Tong, Ying Wang, et al.
Frontiers in Immunology|April 23, 2026
Engineering antibody-armed oncolytic viruses: design strategies, synergistic mechanisms, and clinical translationXiaozhen Kang, Xue Yang, Hui Wu, et al.
Scientific Reports|February 22, 2018
Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicinFan Ni, Xianbo Huang, Zhenzhen Chen, et al.
Mini Reviews in Medicinal Chemistry|September 19, 2023
Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's LymphomaShuxian Liu, Minghao Xu, Lei Zhong, et al.
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Cancers|September 28, 2024
Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug CandidatesLingyan Yu, Yuyueyang Qiu, Xiangmin Tong
Frontiers in Immunology|June 1, 2026
Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistanceXiaozhen Kang, Xiangmin Tong, Shibing Wang
International Journal of Hematology|December 3, 2013
Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutationWeiyi Xu, Baode Chen, Xiangmin Tong
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|July 17, 2019
[Effects of aerobic glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma]Li Xu, Ming Xu, Xiangmin Tong
Frontiers in Pharmacology|March 28, 2019
Carbon-Based Nanomaterials for Biomedical Applications: A Recent StudyDebabrata Maiti, Xiangmin Tong, Xiaozhou Mou, et al.
International Journal of Medical Sciences|September 17, 2025
Overcoming the Delivery Challenges in CRISPR/Cas9 Gene Editing for Effective Cancer Treatment: A Review of Delivery SystemsShuting Tang, Xiaoyi Chen, Xiangmin Tong, et al.
Cell Death & Disease|December 21, 2021
WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemiaYunqi Zhu, Xiangmin Tong, Ying Wang, et al.
Frontiers in Immunology|April 23, 2026
Engineering antibody-armed oncolytic viruses: design strategies, synergistic mechanisms, and clinical translationXiaozhen Kang, Xue Yang, Hui Wu, et al.
Scientific Reports|February 22, 2018
Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicinFan Ni, Xianbo Huang, Zhenzhen Chen, et al.
Mini Reviews in Medicinal Chemistry|September 19, 2023
Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's LymphomaShuxian Liu, Minghao Xu, Lei Zhong, et al.
Pageof 13